Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Burning mouth syndrome: A novel treatment
2023-509727-40-00Phase 2Authorised
- Sponsor
- Malmö University
- Start
- Apr 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, single-arm trial of clonazepam in glossodynia (BMS), sponsored by Malmö University. Primary endpoints: Overall oral mucosa pain intensity, Patient global impression of change (PGIC) and 1 more. Planned start Apr 2024; status: authorised.
02
Drugs
clonazepam
03
Conditions
glossodynia (BMS)
Beyond the preview
Go deeper on 2023-509727-40-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-509727-40-00.